Background and Purpose-There is controversy and little information about whether individual proton pump inhibitors (PPIs) differentially alter the effectiveness of clopidogrel in reducing ischemic stroke risk. We, therefore, aimed to elucidate the risk of ischemic stroke among concomitant users of clopidogrel and individual PPIs. Methods-We conducted a propensity score-adjusted cohort study of adult new users of clopidogrel, using 1999 to 2009 Medicaid claims from 5 large states. Exposures were defined by prescriptions for esomeprazole, lansoprazole, omeprazole, rabeprazole, and pantoprazole-with pantoprazole serving as the referent. The end point was hospitalization for acute ischemic stroke, defined by International Classification of Diseases Ninth Revision Clinical Modification codes in the principal position on inpatient claims, within 180 days of concomitant therapy initiation. Results-Among 325 559 concomitant users of clopidogrel and a PPI, we identified 1667 ischemic strokes for an annual incidence of 2.4% (95% confidence interval, 2.3-2.5). Adjusted hazard ratios for ischemic stroke versus pantoprazole were 0.98 (0.82-1.17) for esomeprazole; 1.06 (0.92-1.21) for lansoprazole; 0.98 (0.85-1.15) for omeprazole; and 0.85 (0.63-1.13) for rabeprazole. Conclusions-PPIs of interest did not increase the rate of ischemic stroke among clopidogrel users when compared with pantoprazole, a PPI thought to be devoid of the potential to interact with clopidogrel. 
C lopidogrel reduces the rate of cerebrovascular and cardiovascular events in patients with acute coronary syndrome (ACS), recent acute myocardial infarction (AMI) or stroke, and those with peripheral artery disease. Clopidogrel itself is pharmacologically inactive and must be converted to an active metabolite through a multistep process mediated by multiple cytochrome P-450 (CYP) isozymes.
1 CYP2C19 is thought to contribute to 45% of the metabolism of clopidogrel to an inactive intermediate, and to 21% of the conversion of the intermediate to the active form. 2 This has led to significant concern that drugs inhibiting CYP2C19 (including some commonly used proton pump inhibitors [PPIs] ) might reduce clopidogrel's effectiveness. For example, a 2009 Food and Drug Administration public health advisory warned that patients taking clopidogrel should avoid omeprazole and esomeprazole, both of which inhibit CYP2C19. 3 Despite the warning, others have questioned the importance of CYP2C19 in clopidogrel activation 4, 5 in favor of CYP3A4 and paraoxonase-1 pathways. 6, 7 Many studies have examined effects of the potential drug interaction between clopidogrel and PPIs on major adverse cardiovascular events as a combined end point and on AMI. Fewer studies have examined effects of the potential interaction on ischemic stroke. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Among these, only one small study examined the comparative safety of individual PPIs in patients taking clopidogrel. 15 This question is important, as the effects of PPIs on stroke might differ from the effects on the composite major adverse cardiovascular events end point. Therefore,
Defining the Study Cohort
We defined new users of clopidogrel as those with ≥12 months of Medicaid enrollment before their first clopidogrel prescription was dispensed. Among such patients, we then identified the day on which they were first concomitantly exposed to clopidogrel and a PPI; this served as the cohort entry date. Patients were able to enter the cohort in 1 of 3 ways, such as (1) clopidogrel was added to ongoing PPI therapy, (2) clopidogrel and the PPI were initiated on the same day, or (3) a PPI was added to ongoing clopidogrel therapy. Given the aforementioned enrollment requirement, patients had ≥1 year of time before cohort entry, yet were permitted to have baseline periods of variable length (≥12 months) so long as this period was devoid of enrollment interruption. Use of a variable baseline period, such as this, results in less-biased estimates and minimizes residual confounding versus use of a fixed period. 25 Patients were excluded from the study if they were <18 years of age. Patients with a stroke during the baseline period were not excluded, as this could have been the indication for their clopidogrel therapy; rather, history of previous stroke was included in the propensity score.
Follow-up began on cohort entry and continued until the first occurrence of the following: (1) outcome of interest (defined below), (2) death, as assessed by linkage to the Social Security Administration Death Master File, (3) the 181st day of follow-up (see rationale in outcome subsection below), (4) >15-day gap in either clopidogrel or PPI therapy, (5) switch to another PPI, (6) loss of Medicaid eligibility, or (7) the end of the data set. Follow-up time occurring during a period of hospitalization was excluded, although hospitalization did not serve as a censoring event.
Exposure and Covariate Ascertainment
Exposure was defined by the specific PPI agent (dispensed in capsule or tablet form) active on the day of cohort entry. Pantoprazole was selected as the reference PPI, as it (1) is not a potent inhibitor of CYP2C19 [26] [27] [28] ; (2) is considered to have a low potential for drugdrug interactions with clopidogrel 29 ; (3) may not be associated with an increased risk of major adverse cardiovascular events 1, 30 ; and (4) has been recommended by Food and Drug Administration as a PPI to be considered in clopidogrel-treated patients. 31 We considered using rabeprazole as the reference PPI because its metabolism is primarily nonenzymatic. 29 However, rabeprazole was used infrequently, which would have resulted in wide 95% confidence intervals (CIs) for effect estimates of PPIs versus rabeprazole.
We measured numerous baseline potential confounders in the following categories: (1) demographics-age, sex, race, state of residence, calendar year, and dual-eligibility status; (2) health system use factors, measured during baseline-such as numbers of emergency department visits, hospitalizations, ambulatory visits, nursing home residence, and prescription dispensings for unique drugs 32 ; (3) diseases, measured during baseline-such as chronic illnesses (eg, diabetes mellitus), potential risk factors for the outcome (eg, hypertension), medical device use (eg, stent placement), and labeled and off-labeled indications for clopidogrel (eg, AMI); (4) drug markers of chronic diseases, measured during baseline (eg, antidiabetic agents, as a marker of diabetes mellitus); (5) acutely occurring diseases, measured 90 days before cohort entry (eg, infection); and (6) recent drug exposures, measured 30 days before cohort entry (7 days for antimicrobials)-for agents posited to increase or decrease outcome risk (eg, nonsteroidal anti-inflammatory drugs and warfarin, respectively), CYP inhibitors and inducers, and drug markers of acutely occurring diseases (eg, antimicrobial agents). Covariates within each of these groups were used in calculating the propensity scores; Complete listing of covariates used are available in Table I in the online-only Data Supplement.
Outcome Ascertainment
The outcome of interest was hospitalization for acute ischemic stroke occurring within 180 days of cohort entry. Operationally, ischemic stroke was defined by one of the following International Classification of Diseases Ninth Revision Clinical Modification discharge diagnosis codes in the principal position on an inpatient claim: 433.X1 (occlusion and stenosis of precerebral arteries, with cerebral infarction); 434 (occlusion of cerebral arteries); 434.0 or 434.01 (cerebral thrombosis); 434.1 or 434.11 (cerebral embolism); 434.9 or 434.91 (cerebral artery occlusion, unspecified); or 436.X (acute, but ill-defined, cerebrovascular disease). Hospitalizations meeting this definition, yet with a concomitant discharge diagnosis for an intracranial injury (with or without skull fracture, International Classification of Diseases Ninth Revision Clinical Modification 800.X-804.X or 850.X-854.X) were excluded, 33 as such ischemic stroke events were probably because of the injury itself rather than a drug interaction. This algorithm, which we have used previously, 34, 35 has a sensitivity, specificity and positive predictive value of 74%, 95%, and 88%, respectively. 33 The restriction of ischemic stroke events of interest to the first 180 days of follow-up was intended to minimize the effect of depletion of susceptible person-time, 36 as loss of the protective effect of clopidogrel would be expected to manifest relatively early. 37, 38 This restriction was lifted in a sensitivity analysis that identified ischemic stroke outcomes in all available person-time.
Statistical Analysis
We first generated descriptive statistics for baseline covariates and calculated incidence and unadjusted association measures, the latter via Cox proportional-hazards regression. We then generated a propensity score vector using multinomial logistic regression 39 -with one propensity score calculated for each PPI versus referent in a single model. For each subject, each PPI-specific propensity score was included in the outcome model as a continuous covariate. 40 We assessed the goodness-of-fit of the propensity score model using Austin's weighted conditional standardized difference method. 41 This approach compares conditional differences in baseline covariates between exposure groups. Propensity score-adjusted hazard ratios (HRs) and 95% CIs were calculated via Cox proportionalhazards regression. Proportional hazards assumptions were examined via inclusion of an interaction term of exposure by survival time.
To account for potential residual imbalance in baseline differences (ie, those not accounted for via propensity score adjustment), we conducted a sensitivity analysis, in which we added covariates to the outcome model if ≥1 of their weighted conditional standardized differences exceeded 0.1.
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A prespecified secondary analysis included the examination of ischemic stroke risk excluding patients enrolled in managed care plans, as Centers for Medicare and Medicaid Services claims may be incomplete for such patients. 42 Post hoc secondary analyses included the examination of ischemic stroke risk among patients with a hospitalization on the day of or within the 29 days before cohort entry for (1) ACS, (2) carotid revascularization/stenting, (3) coronary stenting, (4) other vascular stenting, and (5) AMI. These may represent highrisk periods during which clopidogrel activation would be critical. 43 Statistical analyses were conducted using SAS v9.3 (SAS Institute Inc, Cary, NC) and Stata MP v13.1 (StataCorp LP, College Station, TX).
Results
We identified 325 559 concomitant users of clopidogrel and a PPI. Overall, such patients contributed 70 274 person-years of concomitant exposure, among which we identified 1667 ischemic stroke events (unadjusted rate=2. 4 Table; all measured characteristics, without regard to cohort prevalence, are presented in Table I in the online-only Data Supplement. Standardized mean differences and weighted conditional standardized differences are presented to facilitate the evaluation of potential imbalance in baseline covariates versus pantoprazole, before and after conditioning on propensity score, respectively. For a given PPI versus pantoprazole, the vast majority of baseline covariates were balanced. Propensity score-adjusted HRs for ischemic stroke are presented in Figure 1 . Both unadjusted and adjusted HRs for the sensitivity analyses that did not impose a maximum follow-up time of 180 days and excluded patients with managed care coverage, respectively, yielded HRs similar to those presented in Figure 1 (data not shown).
A sensitivity analysis to account for potential residual imbalance in baseline differences was conducted; this model adjusted for 29 covariates in addition to propensity scores, each of which had weighted conditional standardized differences >0.1. Adjusted HRs arising from this model were 0.99 (0.83-1.18) for esomeprazole, 1.05 (0.91-1.20) for lansoprazole, 0.98 (0.84-1.15) for omeprazole, and 0.85 (0.63-1.13) for rabeprazole, each versus pantoprazole. The similarity of these results to those presented in Figure 1 suggests no effect of imbalance in measured covariates. Therefore, all other modeled results adjusted solely for the calculated propensity scores.
Results from post hoc sensitivity analyses examining potential high-risk subgroups of patients recently hospitalized (in which clopidogrel activation may be critical) as effect modifiers, are ACS indicates acute coronary syndrome; CAO, coronary artery occlusion; CMS, Centers for Medicare and Medicaid Services; COPD, chronic obstructive pulmonary disease; ED, emergency department; ICD, implantable cardioverter-defibrillator; MAOI, monoamine oxidase inhibitor; MI, myocardial infarction; NSAID, nonsteroidal anti-inflammatory drug; PPI, proton pump inhibitor; SMD, standardized mean difference (vs pantoprazole); SNRI, serotonin and norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; and WCSD, weighted conditional standardized difference (vs pantoprazole).
*Cohort prevalence >30% for disease and >20% for drugs. †Baseline covariate, in addition to propensity score, included in the proportional-hazards model for the sensitivity analysis to control for potential residual imbalance in exposure groups; covariates capturing numbers of healthcare visits by site were included in this model as categorical, not continuous measures; the following additional covariates, not meeting the cohort prevalence threshold described above, were also included in this model: acute renal failure, chronic renal failure, substance abuse, recent infectious and parasitic diseases (all other), and recent serious infection (not already coded within infectious and parasitic diseases).
‡Not considered in the propensity score. ) and with a recent cohort study. 17 In propensity score-adjusted models, ischemic stroke rates for clopidogrel with individual PPIs of interest were no greater than that for clopidogrel+pantoprazole. Although the HR for rabeprazole was consistent with a protective effect versus pantoprazole, the 95% CI included the null value.
In the post hoc subgroup analysis of patients recently hospitalized for ACS, clopidogrel+lansoprazole was associated with a 40% increased rate of ischemic stroke versus clopidogrel+pantoprazole. If causal, the magnitude of this association would suggest a complete nullification of clopidogrel's effect, based on findings from the Clopidogrel in HighRisk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE) 46 and Fast Assessment of Stroke and Transient Ischaemic Attack to Prevent Early Recurrence (FASTER) 47 trials, in which clopidogrel+aspirin in patients with an acute transient ischemic attack or minor stroke was associated with HRs ≈0.70 compared with aspirin alone (1/0.7=1.4). However, our subgroup finding for clopidogrel+lansoprazole should be interpreted with great caution for several reasons. First, we are unaware of a mechanism, by which lansoprazole alone would exert this effect. Second, the complete nullification of clopidogrel's pharmacodynamic effect by lansoprazole alone seems implausible, especially because PPIs have modest effects on adenosine diphosphateinduced platelet aggregation 48, 49 and aggregation inhibition is probably less for lansoprazole versus other PPIs. 50 Third, this subgroup analysis was not based on an a priori hypothesis. Finally, the overall P values for the among-PPI difference in the rate of stroke among those with recent ACS hospitalization and among those with recent AMI were not statistically significant. Given this, we hesitate to interpret the potential importance of this subgroup finding and strongly suggest that it be independently confirmed in a study designed to answer this particular question.
Among the handful of studies that have examined the association of clopidogrel and PPIs on ischemic stroke as a standalone outcome (Table II in the online-only Data Supplement), only that by Simon et al 15 reported risks by individual PPI. Yet, their study only examined stroke events (n=7) occurring among ≈1500 inpatients admitted with an AMI. Interpretation of Simon et al's 15 results are limited by their comparison with a PPI-unexposed referent, examination of stroke only during hospitalization, small sample size leading to wide CIs, and inability to calculate an effect estimate for lansoprazole. The prematurely terminated Clopidogrel and the Optimization of Gastrointestinal Events Trial (COGENT) 9 -the only randomized study designed to test the hypothesis of a clopidogrel+PPI interaction-examined ischemic stroke risk only for omeprazole, finding no difference between fixed-dose combination clopidogrel+omeprazole versus clopidogrel alone (P=0.43). This is consistent with our findings.
Comparing our findings to expectations based on underlying biology is challenging given inconsistencies in measurements of the antiplatelet effect of clopidogrel (even in the absence of a PPI) 1 and ongoing controversies on (1) the metabolism of clopidogrel, (2) the concomitant effect of PPIs on inhibition of platelet reactivity, and (3) the role of genetics. If pharmacological inhibition of CYP2C19 reduces the effect of clopidogrel, our finding of no difference in ischemic stroke risk among individual PPIs is inconsistent with in vitro findings suggesting that there are multifold differences in the strength of CYP2C19 inhibition by PPI. 28 An alternative interpretation is that, despite a strong direct-acting inhibition of CYP2C19 by lansoprazole (the most potent inhibitor of this isozyme 28 ), the interaction may rarely manifest clinically. This interpretation is consistent with findings that the inhibitory effect of lansoprazole on clopidogrel activation does not manifest in vivo. 51, 52 Others although have argued that irreversible metabolism-dependent (rather than direct) inhibition of this isozyme by omeprazole and esomeprazole has more profound ramifications. 26 Yet, our findings demonstrated no increase in ischemic stroke risk for omeprazole or esomeprazole. 53, 54 Our study has important strengths. It is the first to compare risk of ischemic stroke solely in community-dwelling users of clopidogrel plus individual PPIs. Our propensity score adjustment and subsequent sensitivity analysis served to minimize confounding. Furthermore, our large sample size allowed for the examination of associations in subgroups of interest. Finally, our algorithm to identify stroke has an excellent positive predictive value and good sensitivity.
Our study also has limitations. First, we did not have access to biosamples and were, therefore, unable to examine genetic polymorphisms in CYP enzymes, p-glycoprotein transporters, or P2Y 12 receptors. Second, we did not have data on adherence to prescribed clopidogrel and PPI therapies. Third, administrative databases may poorly capture some lifestyle behaviors and nonprescription therapies that may modify stroke risk. Regardless, such factors seem unlikely to differ substantially by PPI exposure. Fourth, as with all nonexperimental studies, there may be residual confounding. Finally, our results may not be generalizable beyond a Medicaid population. Nevertheless, this population was specifically selected for study given its inherent vulnerability and inclusion of large numbers of women and minorities-groups typically understudied.
Conclusions
This study provides evidence that the concomitant use of clopidogrel with esomeprazole, lansoprazole, omeprazole, or rabeprazole does not increase the risk of ischemic stroke when compared with pantoprazole, a PPI thought not to interact with clopidogrel.
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